AstraZeneca's Gefurulimab Meets Phase III Endpoints in Myasthenia Gravis but Lags Behind Competitor Therapies
核心洞察
AstraZeneca's gefurulimab achieved a statistically significant 1.6-point improvement in MG-ADL scores compared to placebo in the Phase III PREVAIL study for generalized myasthenia gravis (搜索).
The complement 5 (搜索) inhibitor demonstrated inferior efficacy compared to rival therapies, including UCB (搜索)'s Rystiggo which showed up to 2.6-point MG-ADL improvements and AstraZeneca's own Soliris and Ultomiris.
Gefurulimab showed favorable safety profile with mild-to-moderate adverse events and offers subcutaneous administration, potentially positioning it to compete in the $6.1 billion gMG market as treatment paradigms shift toward self-administered therapies.
AstraZeneca's gefurulimab achieved its primary endpoint in a Phase III trial for generalized myasthenia gravis (搜索) (gMG), but the complement 5 (搜索) inhibitor failed to match the efficacy demonstrated by competing therapies in the crowded autoimmune disorder market.
In the Phase III PREVAIL study (NCT05556096), gefurulimab delivered a statistically significant 1.6-point improvement in myasthenia gravis (搜索) activities of daily living (MG-ADL) scores from baseline compared with placebo. The positive impact on MG-ADL was observed after one week of treatment and maintained over the 26-week study period.
Competitive Landscape Challenges
Despite meeting its primary endpoint, gefurulimab's efficacy fell short of established benchmarks in the gMG space. UCB (搜索)'s Rystiggo (rozanolixizumab) reduced MG-ADL values by up to 2.6 points in the Phase III MycarinG study, significantly outperforming gefurulimab's 1.6-point improvement.
The drug's performance also lagged behind other therapies in development and AstraZeneca's own portfolio. Regeneron's Phase III candidate cemdisiran demonstrated superior MG-ADL improvements, while AstraZeneca's existing gMG drugs Soliris (eculizumab) and Ultomiris (ravulizumab) triggered 2.3, 1.7, and 2.09-point drops respectively in their late-stage trials.
Secondary Endpoint Success
Gefurulimab showed more promising results on secondary measures, significantly reducing quantitative myasthenia gravis (搜索) (QMG) total scores with a 1.8-point reduction from baseline by week four. This effect deepened over time, with patients experiencing a mean 2.1-point drop in QMG scores by week 36.
QMG serves as a comprehensive clinical outcome measure in gMG, incorporating 13 different measures of muscular, motor and respiratory function to provide a broad assessment of patient quality of life.
Patient Population and Safety Profile
The therapeutic benefits were observed specifically in patients with anti-acetylcholine receptor (搜索) (AChR (搜索)) antibody-positive disease, which represents 85% of the gMG population. The subcutaneous drug demonstrated a safety and tolerability profile similar to Soliris and Ultomiris, with treatment-emergent adverse events predominantly mild-to-moderate in severity.
The most common adverse events included headache, injection site reactions, and diarrhea. AstraZeneca acquired rights to all three drugs through its $39 billion acquisition of Alexion Pharmaceuticals in 2021.
Market Positioning and Future Outlook
If approved, gefurulimab would become AstraZeneca's third targeted therapy in the gMG market, joining Soliris and Ultomiris in an indication valued at $6.1 billion in 2024 according to GlobalData analysis.
The potential approval comes at a strategic time for AstraZeneca, as analysts forecast declining market share for the company's existing gMG therapies. Ultomiris sales are expected to grow until 2029 but face significant decline thereafter, with profits projected to halve from $2.41 billion to $1.2 billion between 2029 and 2033. Similarly, Soliris is expected to peak at $1.5 billion in 2026 before declining to $1 billion by 2033.
This market erosion is attributed to increasing competition from subcutaneous therapies including UCB (搜索)'s Zilbrysq (zilucoplan) and Rystiggo, as well as Argenx's Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), which offer enhanced patient convenience over intravenous alternatives.
Gefurulimab's subcutaneous administration aligns with the treatment paradigm's evolution toward self-administered therapies, potentially offering AstraZeneca renewed competitive positioning in the gMG market despite its modest efficacy profile relative to existing options.